{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:19:03Z","timestamp":1788499143854,"version":"build-2803163510"},"reference-count":26,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"abstract":"<jats:p>\n                    Advances in biologics and model\u2010informed drug discovery and development (MID3) are transforming the treatment of immune\u2010mediated inflammatory diseases (IMIDs). By integrating pharmacokinetics and pharmacodynamics, MID3 enables mechanism\u2010based, patient\u2010centered strategies to optimize therapies, strengthen benefit\u2013risk assessment, and advance precision medicine. Innovations such as cytokine inhibitors, bispecific antibodies, antibody\u2013drug conjugates, and mRNA therapies have expanded treatment options across dermatology, rheumatology, gastroenterology, and respiratory medicine. The rapid development of JAK\u2010 and interleukin\u2010targeted agents underscores the shift toward individualized, mechanistically driven therapies. At ASCPT 2025, the session \u201c\n                    <jats:italic>Transformative Advancements in the Treatment of IMIDs: Integrating Patient\u2010Centric Clinical Pharmacology with Translational MID3 for Biologics<\/jats:italic>\n                    \u201d brought together experts from academia, industry, and regulatory agencies and emphasized how translational MID3 and precision pharmacology are accelerating the next generation of patient\u2010tailored biologic therapies, with case studies in inflammatory bowel disease, systemic lupus erythematosus, and rheumatology.\n                  <\/jats:p>","DOI":"10.1002\/cpt.70471","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:04:43Z","timestamp":1788498283000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrating Patient\u2010Centric Clinical Pharmacology and\n                    <scp>MID3<\/scp>\n                    to Advance Biologic Development in Immune\u2010Mediated Inflammatory Diseases"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9794-8601","authenticated-orcid":false,"given":"Sihem","family":"Ait\u2010Oudhia","sequence":"first","affiliation":[{"name":"Quantitative Pharmacology and Pharmacometrics (QP2) Merck &amp; Co., Inc  Rahway New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8547-5744","authenticated-orcid":false,"given":"Li","family":"Zhang","sequence":"additional","affiliation":[{"name":"Quantitative Clinical Pharmacology Daiichi Sankyo  Basking Ridge New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0551-3892","authenticated-orcid":false,"given":"Dipak S.","family":"Pisal","sequence":"additional","affiliation":[{"name":"Division of Inflammation and Immune Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences Center for Drug Evaluation and Research, US Food and Drug Administration  Silver Spring Maryland 20993 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7932-8599","authenticated-orcid":false,"given":"Brian","family":"Cicali","sequence":"additional","affiliation":[{"name":"Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics College of Pharmacy, University of Florida  Orlando Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"e_1_2_8_1_1","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/cpt.3636","article-title":"Impact of model\u2010informed drug development on drug development cycle times and clinical trial cost","volume":"118","author":"Sahasrabudhe V.","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"key":"e_1_2_8_2_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1393463","article-title":"Anti\u2010IL23\/12 agents and JAK inhibitors for inflammatory bowel disease","volume":"15","author":"Tian Z.","year":"2024","journal-title":"Front. Immunol."},{"key":"e_1_2_8_3_1","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaci.2022.12.816","article-title":"Biologics and JAK inhibitors for the treatment of monogenic systemic autoinflammatory diseases in children","volume":"151","author":"Du Y.","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"e_1_2_8_4_1","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/s41586-025-08940-0","article-title":"Global evolution of inflammatory bowel disease across epidemiologic stages","volume":"642","author":"Hracs L.","year":"2025","journal-title":"Nature"},{"key":"e_1_2_8_5_1","article-title":"Crohn's disease and ulcerative colitis: from pathophysiology to novel therapeutic approaches","volume":"12","author":"Long D.","year":"2024","journal-title":"Biomedicine"},{"key":"e_1_2_8_6_1","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1053\/j.gastro.2018.01.043","article-title":"Pharmacokinetics and exposure response relationships of Ustekinumab in patients with Crohn's disease","volume":"154","author":"Adedokun O.J.","year":"2018","journal-title":"Gastroenterology"},{"key":"e_1_2_8_7_1","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1053\/j.gastro.2022.12.007","article-title":"AGA clinical practice guideline on the role of biomarkers for the Management of Ulcerative Colitis","volume":"164","author":"Singh S.","year":"2023","journal-title":"Gastroenterology"},{"key":"e_1_2_8_8_1","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1136\/gutjnl-2024-332504","article-title":"Targeting TL1A and DR3: the new frontier of anti\u2010cytokine therapy in IBD","volume":"74","author":"Bamias G.","year":"2025","journal-title":"Gut"},{"key":"e_1_2_8_9_1","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.653924","article-title":"Precision medicine in inflammatory bowel diseases","volume":"12","author":"Marafini I.","year":"2021","journal-title":"Front. Pharmacol."},{"key":"e_1_2_8_10_1","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1001\/jama.2024.2315","article-title":"Systemic lupus erythematosus: a review","volume":"331","author":"Siegel C.H.","year":"2024","journal-title":"JAMA"},{"key":"e_1_2_8_11_1","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s10067-020-05226-w","article-title":"Insights into the choice between intravenous infusion and subcutaneous injection: physician and patient characteristics driving treatment in SLE","volume":"40","author":"Bell C.F.","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"e_1_2_8_12_1","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.molmed.2020.09.009","article-title":"Leveraging heterogeneity in systemic lupus erythematosus for new therapies","volume":"27","author":"Allen M.E.","year":"2021","journal-title":"Trends Mol. Med."},{"key":"e_1_2_8_13_1","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41586-022-04642-z","article-title":"TLR7 gain\u2010of\u2010function genetic variation causes human lupus","volume":"605","author":"Brown G.J.","year":"2022","journal-title":"Nature"},{"key":"e_1_2_8_14_1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/intimm\/dxaf046","article-title":"Anti\u2010human TLR7 antibody for therapeutic intervention in systemic lupus erythematosus","volume":"38","author":"Fukui R.","year":"2025","journal-title":"Int. Immunol."},{"key":"e_1_2_8_15_1","unstructured":"Akhlaq A.Trends in Disparity by Age Sex and Race for Systemic Lupus Erythematosus Patients inACR Convergence2021(2021)."},{"key":"e_1_2_8_16_1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/jcph.6117","article-title":"First\u2010in\u2010human study of the safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamics of DS\u20107011a, an anti\u2010TLR7 antagonistic monoclonal antibody for the treatment of systemic lupus erythematosus","volume":"65","author":"Senaldi G.","year":"2024","journal-title":"J. Clin. Pharmacol."},{"key":"e_1_2_8_17_1","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2024-eular.1224","article-title":"Pharmacokinetic pharmacodynamic relationship justifies dose selection of DS\u20107011a, an anti\u2010TLR7 monoclonal antibody, for the treatment of Asian participants in an ongoing global phase 1b study of DS\u20107011a in systemic lupus erythematosus","volume":"83","author":"Zhang L.","year":"2024","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"e_1_2_8_18_1","first-page":"i67","article-title":"The effect of ethnicity and genetic ancestry on the epidemiology, clinical features and outcome of systemic lupus erythematosus","volume":"56","author":"Lewis M.J.","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"e_1_2_8_19_1","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/cpt.3456","article-title":"New drug development strategy in Japan: flexibility in guideline adherence","volume":"117","author":"Kobayashi M.","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"key":"e_1_2_8_20_1","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/cpt.3216","article-title":"Asia\u2010inclusive global development of Enpatoran: results of an Ethno\u2010bridging study, intrinsic\/extrinsic factor assessments and disease trajectory modeling to inform Design of a Phase II multiregional clinical trial","volume":"115","author":"Klopp\u2010Schulze L.","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"e_1_2_8_21_1","first-page":"4658","article-title":"Selection of the dose for subcutaneous administration to non\u2010Japanese subjects and intravenous administration to Japanese subjects in the first\u2010inhuman study of DS\u20107011a, an anti\u2010TLR7 monoclonal antibody for the treatment of systemic lupus erythematosus","volume":"75","author":"Li Zhang J.T.","year":"2023","journal-title":"Arthritis Rheum."},{"key":"e_1_2_8_22_1","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin C.T.","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"e_1_2_8_23_1","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1056\/NEJMra1406182","article-title":"Ankylosing spondylitis and axial Spondyloarthritis","volume":"374","author":"Taurog J.D.","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"e_1_2_8_24_1","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/s41584-020-0496-z","article-title":"Secukinumab effective for nr\u2010axSpA","volume":"16","author":"Onuora S.","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"e_1_2_8_25_1","unstructured":"COSENTYX\u00ae (secukinumab) injection USPI<https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761349s000lbl.pdf>."},{"key":"e_1_2_8_26_1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/cpt.3464","article-title":"Model\u2010informed drug development\u2010based approval of intravenous Secukinumab for the treatment of adult patients with active psoriatic arthritis, active ankylosing spondylitis, and active non\u2010radiographic axial Spondyloarthritis","volume":"117","author":"Pisal D.S.","year":"2025","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.70471","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpt.70471","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.70471","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:04:47Z","timestamp":1788498287000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.70471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":26,"alternative-id":["10.1002\/cpt.70471"],"URL":"https:\/\/doi.org\/10.1002\/cpt.70471","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"assertion":[{"value":"2026-01-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"cpt.70471"}}